Статья
Место терапии риоцигуатом у пациентов с легочной артериальной гипертензией, ассоциированной с системными заболеваниями соединительной ткани
Легочная гипертензия (ЛГ) может развиваться при различных системных аутоиммунных ревматических заболеваниях (САРЗ), таких как системная склеродермия (ССД), системная красная волчанка, ревматоидный артрит, смешанное заболевание соединительной ткани. Наиболее часто у пациентов с САРЗ развивается ЛГ первой группы по классификации ВОЗ (легочная артериальная гипертензия, ассоциированная с системными заболеваниями соединительной ткани; ЛАГ-СЗСТ). Общая распространенность данной патологии составляет до 15 случаев на 1 миллион взрослого населения. Большинство случаев ЛАГ-СЗСТ обусловлено ССД. Выживаемость больных ЛАГ-СЗСТ в целом ниже, чем выживаемость пациентов с другими формами ЛАГ. Лечение любого САРЗ, в том числе и при развитии ЛАГ, предполагает использование комплексного подхода с применением глюкокортикоидов, болезнь-модифицирующих препаратов течения ревматического заболевания (циклофосфамид, метотрексат, азатиоприн и др.) и генно-инженерных биологических препаратов. Большинству пациентов с ЛАГ-СЗСТ показано назначение специфической таргетной терапии. Представитель нового класса (стимуляторы растворимой гуанилатциулазы (рГЦ)) риоцигуат одобрен для лечения ЛАГ. Препарат обладает уникальным двойным механизмом действия: (1) сенсибилизация рГЦ к эндогенному оксиду азота (NO) путем стабилизации связи NO-рГЦ; (2) прямая NO-независимая стимуляция рГЦ. Для больных СЗСТ-ЛАГ риоцигуат является основной альтернативой ингибиторам фосфодиэстеразы-5, как в качестве монотерапии, так и в качестве комбинированной терапии.
1. Чазова И. Е., Мартынюк Т.В., Валиева З.С., Азизов В.А., Барбараш О.Л., Веселова Т.Н. и др. Евразийские клинические рекомендации по диагностике и лечению легочной гипертензии. Евразийский кардиологический журнал. 2020;1(30):78-122. DOI: 10.24411/2076-4766-2020-10002
2. Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Respiratory Journal. 2015;46(4):903–75. DOI: 10.1183/13993003.01032-2015
3. D’Alonzo GE, Barst RJ, Ayres SM, Brundage BH, Detre KM, Fishman AP et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry. Annals of Internal Medicine. 1991;115(5):343–9. DOI: 10.7326/0003-4819-115-5-343
4. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal. 2019;53(1):1801913. DOI: 10.1183/13993003.01913-2018
5. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al. Pulmonary Arterial Hypertension in France: Results from a National Registry. American Journal of Respiratory and Critical Care Medicine. 2006;173(9):1023–30. DOI: 10.1164/rccm.200510-1668OC
6. Launay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Annals of the Rheumatic Diseases. 2013;72(12):1940–6. DOI: 10.1136/annrheumdis-2012-202489
7. Sanchez O, Sitbon O, Jaïs X, Simonneau G, Humbert M. Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension. Chest. 2006;130(1):182–9. DOI: 10.1378/chest.130.1.182
8. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB et al. Characterization of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension From REVEAL. Chest. 2010;138(6):1383–94. DOI: 10.1378/chest.10-0260
9. Humbert M, Coghlan JG, Ghofrani H-A, Grimminger F, He J-G, Riemekasten G et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Annals of the Rheumatic Diseases. 2017;76(2):422–6. DOI: 10.1136/annrheumdis-2015-209087
10. McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. European Respiratory Review. 2012;21(123):8–18. DOI: 10.1183/09059180.00008211
11. Fayed H, Coghlan JG. Pulmonary Hypertension Associated with Connective Tissue Disease. Seminars in Respiratory and Critical Care Medicine. 2019;40(02):173–83. DOI: 10.1055/s-0039-1685214
12. Zanatta E, Polito P, Famoso G, Larosa M, De Zorzi E, Scarpieri E et al. Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment. Experimental Biology and Medicine. 2019;244(2):120–31. DOI: 10.1177/1535370218824101
13. Mukerjee D, George DSt, Coleiro B, Knight C, Denton CP, Davar J et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Annals of the Rheumatic Diseases. 2003;62(11):1088–93. DOI: 10.1136/ard.62.11.1088
14. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis & Rheumatism. 2005;52(12):3792–800. DOI: 10.1002/art.21433
15. Gaine SP, Rubin LJ. Primary pulmonary hypertension. The Lancet. 1998;352(9129):719–25. DOI: 10.1016/S0140-6736(98)02111-4
16. Чазова И.Е., Архипова О.А., Мартынюк Т.В. Легочная артериальная гипертензия в России: анализ шестилетнего наблюдения по данным Национального регистра. Терапевтический архив. 2019;91(1):25– 31. DOI: 10.26442/00403660.2019.01.000024
17. Mayes MD. Scleroderma epidemiology. Rheumatic Disease Clinics of North America. 2003;29(2):239–54. DOI: 10.1016/S0889-857X(03)00022-X
18. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USAbased registry for pulmonary arterial hypertension: 1982 - 2006. European Respiratory Journal. 2007;30(6):1103–10. DOI: 10.1183/09031936.00042107
19. Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis & Rheumatism. 2009;60(6):1831–9. DOI: 10.1002/art.24525
20. Johnson SR, Granton JT. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. European Respiratory Review. 2011;20(122):277–86. DOI: 10.1183/09059180.00003811
21. Haas C. Pulmonary hypertension associated with systemic lupus erythematosus. Bulletin De l’Academie Nationale De Medecine. 2004;188(6):985–97; discussion 997. PMID: 15651427
22. Arnaud L, Agard C, Haroche J, Cacoub P, Piette J-C, Amoura Z. Hypertension artérielle pulmonaire associée au lupus systémique. La Revue de Médecine Interne. 2011;32(11):689–97. DOI: 10.1016/j.revmed.2011.01.002
23. Ghofraniha L, Mirfeizi Z, Seyyedi Khabbaz F, Vakilian F, Eslami S. Correlation of echocardiographic findings of pulmonary hypertension with six-minute walk test and plasma pro b-type natriuretic peptide level in systemic lupus erythematous. Electronic Physician. 2017;9(8):5122–8. DOI: 10.19082/5122
24. Asif S, Rasheed A, Mahmud T-H, Asghar A. Frequency and predictors of pulmonary hypertension in patients with Systemic Lupus Erythematosus. Pakistan Journal of Medical Sciences. 2019;35(1):86–9. DOI: 10.12669/pjms.35.1.405
25. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry. Chest. 2012;142(2):448–56. DOI: 10.1378/chest.11-1460
26. Galiè N, Manes A, Farahani KV, Pelino F, Palazzini M, Negro L et al. Pulmonary arterial hypertension associated to connective tissue diseases. Lupus. 2005;14(9):713–7. DOI: 10.1191/0961203305lu2206oa
27. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JSR, Vrapi F et al. Connective Tissue Disease–associated Pulmonary Arterial Hypertension in the Modern Treatment Era. American Journal of Respiratory and Critical Care Medicine. 2009;179(2):151–7. DOI: 10.1164/rccm.200806-953OC
28. Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM et al. Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry. Chest. 2014;146(6):1494–504. DOI: 10.1378/chest.13-3014
29. Min HK, Lee JH, Jung SM, Lee J, Kang KY, Kwok S-K et al. Pulmonary hypertension in systemic lupus erythematosus: an independent predictor of patient survival. The Korean Journal of Internal Medicine. 2015;30(2):232–41. DOI: 10.3904/kjim.2015.30.2.232
30. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. European Respiratory Journal. 2003;22(2):358–63. DOI: 10.1183/09031936.03.00038903
31. Nicolls MR, Voelkel NF. The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 2017;195(10):1292–9. DOI: 10.1164/rccm.201608-1630PP
32. Dhala A. Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Current Status and Future Direction. Clinical and Developmental Immunology. 2012;2012:854941. DOI: 10.1155/2012/854941
33. Sasaki N, Kamataki A, Sawai T. A Histopathological Study of Pulmonary Hypertension in Connective Tissue Disease. Allergology International. 2011;60(4):411–7. DOI: 10.2332/allergolint.11-RAI-0337
34. Kato Y, Kasama T, Soejima M, Kubota T. Anti-enolase 1 antibodies from a patient with systemic lupus erythematosus accompanied by pulmonary arterial hypertension promote migration of pulmonary artery smooth muscle cells. Immunology Letters. 2020;218:22–9. DOI: 10.1016/j.imlet.2019.12.005
35. Lee JH, Im Cho K. Arterial stiffness, antiphospholipid antibodies, and pulmonary arterial hypertension in systemic lupus erythematosus. Journal of Cardiology. 2014;64(6):450–5. DOI: 10.1016/j.jjcc.2014.02.030
36. Houman MH, Smiti-Khanfir M, Ghorbell IB, Miled M. Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients. Lupus. 2004;13(3):204–11. DOI: 10.1191/0961203303lu530xx
37. Huang C, Li M, Liu Y, Wang Q, Guo X, Zhao J et al. Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients. Medicine. 2016;95(10):e2761. DOI: 10.1097/MD.0000000000002761
38. Kahler CM, Colleselli D. Pulmonary arterial hypertension (PAH) in connective tissue diseases. Rheumatology. 2006;45(Suppl 3):iii11– 3. DOI: 10.1093/rheumatology/kel291
39. Lai Y-C, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary Arterial Hypertension: The Clinical Syndrome. Circulation Research. 2014;115(1):115–30. DOI: 10.1161/CIRCRESAHA.115.301146
40. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovascular Research. 2004;61(2):227–37. DOI: 10.1016/j.cardiores.2003.11.026
41. Chester AH, Yacoub MH, Moncada S. Nitric oxide and pulmonary arterial hypertension. Global Cardiology Science and Practice. 2017;2017(2):14. DOI: 10.21542/gcsp.2017.14
42. Mitchell JA, Ahmetaj-Shala B, Kirkby NS, Wright WR, Mackenzie LS, Reed DM et al. Role of prostacyclin in pulmonary hypertension. Global Cardiology Science and Practice. 2014;2014(4):382–393. DOI: 10.5339/gcsp.2014.53
43. Chazova I.E., Martynyuk T.V. Pulmonary hypertension. – M.: Praktika;2015. - 928 p.. ISBN 978-5-89816-138-5
44. Lundberg JO, Gladwin MT, Weitzberg E. Strategies to increase nitric oxide signalling in cardiovascular disease. Nature Reviews Drug Discovery. 2015;14(9):623–41. DOI: 10.1038/nrd4623
45. Koshland D. The molecule of the year. Science. 1992;258(5090):1861–1861. DOI: 10.1126/science.1470903
46. Chatterjee A, Catravas JD. Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascular Pharmacology. 2008;49(4– 6):134–40. DOI: 10.1016/j.vph.2008.06.008
47. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HHHW, Stasch J-P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nature Reviews Drug Discovery. 2006;5(9):755–68. DOI: 10.1038/nrd2038
48. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nature Biotechnology. 2013;31(12):1064. DOI: 10.1038/nbt1213-1064b
49. Шмальц А.А., Горбачевский С.В. Риоцигуат и силденафил в лечении легочной гипертензии: сходства и различия. Пульмонология. 2016;26(1):85–91. DOI: 10.18093/0869-0189-2016-26-1-85-91
50. Launay D, Sobanski V, Hachulla E, Humbert M. Pulmonary hypertension in systemic sclerosis: different phenotypes. European Respiratory Review. 2017;26(145):170056. DOI: 10.1183/16000617.0056-2017
51. Weatherald J, Montani D, Jevnikar M, Jaïs X, Savale L, Humbert M. Screening for pulmonary arterial hypertension in systemic sclerosis. European Respiratory Review. 2019;28(153):190023. DOI: 10.1183/16000617.0023-2019
52. Kato M, Atsumi T. Pulmonary arterial hypertension associated with connective tissue diseases: A review focusing on distinctive clinical aspects. European Journal of Clinical Investigation. 2018;48(2):e12876. DOI: 10.1111/eci.12876
53. Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE et al. Recommendations for Screening and Detection of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Pulmonary Hypertension in Connective Tissue Diseases. Arthritis & Rheumatism. 2013;65(12):3194–201. DOI: 10.1002/art.38172
54. Nasonov E.L. Russian clinical guidelines. Rheumatology. -M.: GEOTAR-Media;2017. - 464 p.. ISBN 978-5-9704-4261-6
55. Jais X, Launay D, Yaici A, Le Pavec J, Tchérakian C, Sitbon O et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease–associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases. Arthritis & Rheumatism. 2008;58(2):521–31. DOI: 10.1002/art.23303
56. Sobanski V, Launay D, Hachulla E, Humbert M. Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). Current Rheumatology Reports. 2016;18(2):10. DOI: 10.1007/s11926-015-0560-x
57. Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, Ishii T, Satoh K, Miura Y et al. Intensive Immunosuppressive Therapy Improves Pulmonary Hemodynamics and Long-Term Prognosis in Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Circulation Journal. 2011;75(11):2668–74. DOI: 10.1253/circj.CJ-11-0473
58. Montani D, Savale L, Natali D, Jais X, Herve P, Garcia G et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. European Heart Journal. 2010;31(15):1898–907. DOI: 10.1093/eurheartj/ehq170
59. Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Rouzic EML et al. Five-Year Outcomes of Patients Enrolled in the REVEAL Registry. Chest. 2015;148(4):1043–54. DOI: 10.1378/chest.15-0300
60. Stasch J-P, Pacher P, Evgenov OV. Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease. Circulation. 2011;123(20):2263–73. DOI: 10.1161/CIRCULATIONAHA.110.981738
61. Ghofrani H-A, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z-C et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2013;369(4):330–40. DOI: 10.1056/NEJMoa1209655
62. Rubin LJ, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z-C et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). European Respiratory Journal. 2015;45(5):1303–13. DOI: 10.1183/09031936.00090614
63. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. The Journal of Rheumatology. 2007;34(12):2417– 22. PMID: 17985403
64. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease: A Randomized, Controlled Trial. Annals of Internal Medicine. 2000;132(6):425–34. DOI: 10.7326/0003-4819-132-6-200003210-00002
65. Denton CP, Pope JE, Peter H-H, Gabrielli A, Boonstra A, van den Hoogen FHJ et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Annals of the Rheumatic Diseases. 2007;67(9):1222–8. DOI: 10.1136/ard.2007.079921
66. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE et al. Pulmonary Arterial Hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376–87. DOI: 10.1378/chest.09-1140
67. Hurdman J, Condliffe R, Elliot CA, Davies C, Hill C, Wild JM et al. ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. European Respiratory Journal. 2012;39(4):945–55. DOI: 10.1183/09031936.00078411
68. Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. International Journal of Cardiology. 2013;168(2):871–80. DOI: 10.1016/j.ijcard.2012.10.026
69. Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vascular Health and Risk Management. 2006;2(4):411– 22. DOI: 10.2147/vhrm.2006.2.4.411
70. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nature Reviews Drug Discovery. 2006;5(8):689–702. DOI: 10.1038/nrd2030
71. Giaid A, Saleh D. Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension. New England Journal of Medicine. 1995;333(4):214–21. DOI: 10.1056/NEJM199507273330403
72. Kielstein JT, Bode-Böger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D et al. Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(7):1414–8. DOI: 10.1161/01.ATV.0000168414.06853.f0
73. Migneault A, Sauvageau S, Villeneuve L, Thorin E, Fournier A, Leblanc N et al. Chronically Elevated Endothelin Levels Reduce Pulmonary Vascular Reactivity to Nitric Oxide. American Journal of Respiratory and Critical Care Medicine. 2005;171(5):506–13. DOI: 10.1164/rccm.200403-340OC
74. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacology & Therapeutics. 2009;122(3):216–38. DOI: 10.1016/j.pharmthera.2009.02.009
75. Archer SL, Djaballah K, Humbert M, Kenneth Weir E, Fartoukh M, Dall’Ava-Santucci J et al. Nitric Oxide Deficiency in Fenfluramine- and Dexfenfluramine-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine. 1998;158(4):1061–7. DOI: 10.1164/ajrccm.158.4.9802113
76. Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic Response to Sildenafil, Nitric Oxide, and Iloprost in Primary Pulmonary Hypertension. Chest. 2004;125(2):580–6. DOI: 10.1378/chest.125.2.580
77. Galiè N, Barberà JA, Frost AE, Ghofrani H-A, Hoeper MM, McLaughlin VV et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine. 2015;373(9):834–44. DOI: 10.1056/NEJMoa1413687
78. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine. 2013;369(9):809–18. DOI: 10.1056/NEJMoa1213917
79. Hoeper MM, Simonneau G, Corris PA, Ghofrani H-A, Klinger JR, Langleben D et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. European Respiratory Journal. 2017;50(3):1602425. DOI: 10.1183/13993003.02425-2016
80. Raina A, Benza RL, Farber HW. Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series. Pulmonary Circulation. 2017;7(3):741–6. DOI: 10.1177/2045893217721694